BUFFALO, NY — June 10, 2025 — The Ride for Roswell, one of the USA’s largest cycling events supporting cancer research, returns to Buffalo on Saturday, June 28, 2025. Hosted annually by Roswell Park Comprehensive Cancer Center, this community-wide event brings together riders, volunteers, and supporters to raise funds for cancer research, celebrate survivors, and honor those lost to the disease. 

Tufts researchers have designed a new, next-generation compound with hopes that it could be more effective with fewer side effects than the currently popular GLP-1 drugs. The new drug targets four hormone receptors simultaneously, for a combined effect that modulates hunger, pace of digestion, blood glucose, energy and fat metabolism

CAR-T cells are specialized immune cells genetically modified to recognize and attack cancer cells. Researchers at Nagoya University in Japan and their collaborators have developed new CAR-T cells to target malignant tumors. While similar treatments have worked well for blood cancers, treating solid tumors is more difficult. Their method targeted a protein found in high amounts on many types of cancer cells (Eva1) and successfully eliminated tumors in lab mice.

National Comprehensive Cancer Network and African Cancer Coalition take part in American Cancer Society Global Academy Regional Workshop to improve cancer care in Sub-Saharan Africa.

Compared to stool DNA testing, researchers found that CT colonography is a cost-saving and clinically effective method for colorectal cancer screening, according to a new study.

OXFORD, Miss. – Sea cucumbers are the ocean's janitors, cleaning the seabed and recycling nutrients back into the water. But this humble marine invertebrate could also hold the key to stopping the spread of cancer.

Cancer remains one of the most pressing global health challenges, with millions of new diagnoses each year. While precision medicine and targeted therapies have transformed treatment strategies, many patients still face drug resistance and disease recurrence. A new review published in Genes & Diseases highlights the critical role of patient-derived xenograft (PDX) models, offering a powerful preclinical platform that more accurately mimics human tumors. These models could revolutionize drug development, improve treatment efficacy, and guide personalized therapies.

 

Breast cancer remains the most prevalent malignancy among women worldwide, posing a critical challenge to global health. Amid the complexities of this disease, an emerging focus on metabolic reprogramming has shed light on novel treatment avenues. A newly published review delves into the intricate alterations in glucose, lipid, and amino acid metabolism that drive breast cancer progression and explores promising therapeutic strategies designed to exploit these metabolic dependencies.